These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 7051538)

  • 1. [Experience with the hypolipidemic drug Lipanthyl].
    Vaverková H; Kubasta M; Zmeskal A; Vrublovský P; Skrabalová H; Vlcek L
    Vnitr Lek; 1982 Jul; 28(7):698-704. PubMed ID: 7051538
    [No Abstract]   [Full Text] [Related]  

  • 2. [Efficacy of procetofen (lipanthyl) in hyperlipidemias (author's transl)].
    Stähelin HB; Seiler W; Pult N
    Schweiz Rundsch Med Prax; 1979 Jan; 68(1):24-8. PubMed ID: 760103
    [No Abstract]   [Full Text] [Related]  

  • 3. Cochleovestibular disorders and hyperlipidemia. A controlled trial with fenofibrate.
    Torossian F; Laredo C
    Monogr Atheroscler; 1986; 14():222-9. PubMed ID: 3526130
    [No Abstract]   [Full Text] [Related]  

  • 4. [Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia].
    Sznajd J; Magdoń M; Idzior B; Konarska R; Malczewska M; Czarnecka H
    Przegl Lek; 1984; 41(2):217-21. PubMed ID: 6377392
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of hyperlipoproteinemia with lipanthyl].
    Kalinová M; Zadák Z; Sobotka L
    Cas Lek Cesk; 1983 Feb; 122(7):205-8. PubMed ID: 6831503
    [No Abstract]   [Full Text] [Related]  

  • 6. [Evaluation of the effectiveness of procetofen in the treatment of hypercholesterolemia].
    Kulejewski L; Giec L
    Wiad Lek; 1985 Oct; 38(20):1409-13. PubMed ID: 3913152
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of fenofibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in hypertriglyceridaemic subjects.
    Packard CJ; Caslake MJ; Shepherd J
    Monogr Atheroscler; 1985; 13():142-4. PubMed ID: 4088276
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of lipanthyl in hyperlipoproteinaemic diabetic patients.
    Hajós P; Tornyossi M
    Ther Hung; 1989; 37(3):138-43. PubMed ID: 2588196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CH 13.437 in different types of hyperlipidemia.
    Harvengt C
    Arch Int Pharmacodyn Ther; 1972 Apr; 196():Suppl 196:298+. PubMed ID: 4559547
    [No Abstract]   [Full Text] [Related]  

  • 10. [The effect of lipanthyl therapy on hyperlipoproteinemia type II/a, II/b and IV].
    Karádi I; Pados G; Németh-Csóka M; Romics L
    Orv Hetil; 1988 Aug; 129(33):1757-60. PubMed ID: 3174116
    [No Abstract]   [Full Text] [Related]  

  • 11. Protective role of lipanthyl in women taking oral contraceptives.
    Sásdi A
    Ther Hung; 1991; 39(1):44-6. PubMed ID: 1858074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Procetofen: hemolytic effect in subjects with G6PD deficiency. Description of a case].
    Testa S; Nurra P; Nurra V
    Clin Ter; 1982 Sep; 102(5):519-22. PubMed ID: 7151373
    [No Abstract]   [Full Text] [Related]  

  • 13. Pantethine versus fenofibrate in the treatment of type II hyperlipoproteinemia.
    Postiglione A; Rubba P; Cicerano U; Chierchia I; Mancini M
    Monogr Atheroscler; 1985; 13():145-8. PubMed ID: 3911056
    [No Abstract]   [Full Text] [Related]  

  • 14. [Procetofen in the treatment of hyperlipoproteinaemias (author's transl)].
    Micheli H; Pometta D
    Schweiz Rundsch Med Prax; 1980 Jan; 69(2):42-6. PubMed ID: 7367386
    [No Abstract]   [Full Text] [Related]  

  • 15. [level of 7alpha-hydroxycholesterol in blood plasma as an indicator of cholesterol catabolism in hyperlipidemia and with hypolipidemic therapy].
    Poliakova ED; Ivanova TN; Voshchinnikov EI; Olfer'ev AM; Perova NV
    Vopr Med Khim; 2000; 46(2):168-75. PubMed ID: 10885038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
    Schwartzkopff W; Schilling A
    Med Welt; 1980 Dec; 31(50):1845-50. PubMed ID: 7464535
    [No Abstract]   [Full Text] [Related]  

  • 17. [Milestone in the treatment of diabetic dyslipidemia: the DAIS Study].
    Forster T
    Orv Hetil; 2001 Jul; 142(29):1588-9. PubMed ID: 11494751
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of essential hyperlipidemia with procetofene. Apropos of 100 cases].
    Fromantin M; Gautier D; Bon R
    Sem Hop Ther; 1977; 53(5-6):311-6. PubMed ID: 897691
    [No Abstract]   [Full Text] [Related]  

  • 19. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
    Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
    [No Abstract]   [Full Text] [Related]  

  • 20. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients.
    Boissonnat P; Salen P; Guidollet J; Ferrera R; Dureau G; Ninet J; Renaud S; de Lorgeril M
    Transplantation; 1994 Jul; 58(2):245-7. PubMed ID: 7726891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.